Acute Myeloid Leukemia Coverage From Every Angle

Eunice S. Wang, MD: Clinical Perspective: Treatment Options for Patients With FLT3-Mutated AML

Posted: Tuesday, December 14, 2021

Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses the implications of phase III findings on the benefit of gilteritinib and azacitidine for patients with newly diagnosed FLT3-mutant acute myeloid leukemia who are ineligible for intensive induction chemotherapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.